▎WuXiEdited by Kant Content Team

Johnson & Johnson announced today that the topline results of the Phase 3 clinical trial MDD3001 showed that seltorexant, as an adjunctive treatment for antidepressants, demonstrated efficacy and safety in adult and elderly patients with major depressive disorder (MDD) accompanied by insomnia symptoms.Seltorexant is a potential "first-in-class" selective human orexin-2 receptor antagonist.

Seltorexant is an antidepressant therapy for the treatment of MDD co-developed by Johnson & Johnson and Minerva Neurosciences. It is a potential "first-in-class" oral, specific orexin-2 receptor antagonist. The orexin system in the brain is associated with metabolism, stress response, and maintaining wakefulness.Seltorexant can suppress the hyperarousal symptoms observed in patients with depression by inhibiting the orexin-2 receptor.

In addition, Johnson & Johnson announced the results of Spravato nasal spray as a monotherapy in the Phase 4 clinical trial TRD4005 for patients with treatment-resistant depression (TRD). The study met its primary and secondary endpoints. This randomized, double-blind, multicenter study showed,Spravato provided rapid, statistically significant, and clinically meaningful improvement in depressive symptoms approximately 24 hours after the first dose, and continued to be effective throughout the 4-week treatment period.

Spravato has been approved by the U.S. FDA for use in combination with oral antidepressants to treat adult patients with treatment-resistant depression and adults with major depressive disorder accompanied by suicidal thoughts or behaviors.

Disclaimer: The content team of WuXi AppTec focuses on introducing the research progress in global biopharmaceuticals and health. This article is for information exchange purposes only, and the views expressed in the article do not represent the position of WuXi AppTec, nor does it imply that WuXi AppTec supports or opposes these views. This article is not a recommendation for treatment plans. For guidance on treatment options, please visit a正规 hospital.

Copyright Statement: This article is from the content team of WuXi AppTec. Individuals are welcome to share it on their social media circles, but unauthorized reproduction by media or institutions in any form to other platforms is prohibited. For authorization to reproduce, please reply with "reprint" on the WeChat Official Account of "WuXi AppTec" to obtain reprint guidelines.